Лечение первичного гипотиреоза: нерешенные вопросы

Cover Page

Abstract


Primary hypothyroidism is one of the most common endocrine disorders. According to modern concepts, replacement monotherapy with levothyroxine (L-T4) is the treatment of choice in primary hypothyroidism. In most cases, compensation of hypothyroidism leads to relief of symptoms and, as a consequence, improvement the quality of life. However, according to different authors, 5—10% of patients with hypothyroidism receiving adequate replacement therapy with L-T4 have persistent symptoms of hypothyroidism, increased levels of anxiety and depression. The review discusses approaches to managing of such patients, and as one of the options — transfer to combination therapy with levothyroxine and triiodothyronine (L-T4+T3).

About the authors

Tatyana Borisovna Morgunova

Sechenov First Moscow State Medical University, Moscow

Email: tanmorgun@mail.ru

Russian Federation MD, PhD, assistant professor at the Endocrinology Chair in General Medicine Faculty

Meruert Shayzindinovna Madiyarova

Sechenov First Moscow State Medical University, Moscow

Email: mad-meruert@ya.ru

Russian Federation MD, PhD-student at the Endocrinology Chair in General Medicine Faculty

Valentin Viktorovich Fadeyev

Sechenov First Moscow State Medical University, Moscow

Author for correspondence.
Email: walfad@mail.ru

Russian Federation MD, PhD, Professor, Chief of the Endocrinology Chair in General Medicine Faculty

References

  1. Wiersinga W, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. The Use of L-T4+L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. doi: 10.1159/000339444. PMID: 24782999; PMCID: PMC3821467. Epub 2012 Jun 13.
  2. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014; 35(3):433-512. doi: 10.1210/er.2013-1083. PMID: 24433025. Epub 2014 Jan 16.
  3. Oppenheimer JH, Braverman LE, Toft A, Jackson IM, Ladenson PW. A therapeutic controversy. Thyroid hormone treatment: when and what? J. Clin. Endocrinol. Metab. 1995;80(10):2873-2876.
  4. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028.
  5. Chakera AJ1, Pearce SH, Vaidya B. Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Des Devel Ther. 2012;6:1-11. doi: 10.2147/DDDT.S12894. PMID: 22291465; PMCID: PMC3267517. Epub 2011 Dec 22.
  6. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G, Rago T, Mammoli C, Elisei R, Vitti P. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005 Jan;90(1):124-7. Epub 2004 Oct 13.
  7. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado disease prevalence study. Arch Intern Med.2000;160:526-534.
  8. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom.Clin Endocrinol (Oxf).1991;34(1):77-83.
  9. Leese GP, Jung RT, Scott A, Waugh N, Browning MC. Long term follow-up of treated hyperthyroid and hypothyroid patients.Health Bull (Edinb).1993;51(3):177-83.
  10. Liewendahl K, Helenius T, Lamberg BA, Mähönen H, Wägar G. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy. Acta Endocrinol (Copenh).1987;116(3):418-24.
  11. Díez JJ. Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J Gerontol A Biol Sci Med Sci. 2002;57(5):M315-20.
  12. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95(1):186-93. doi: 10.1210/jc.2009-1625. PMID: 19906785. Epub 2009 Nov 11.
  13. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community- based randomized controlled trial. J Clin Endocrinol Metab. 2005;90:805–812. Epub 2004 Dec 7.
  14. Seshadri MS, Samuel BU, Kanagasabapathy AS, Cherian AM. Clinical scoring system for hypothyroidism: is it useful? J Gen Intern Med.1989;4(6):490-2.
  15. Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BG, Dhaliwal SS, Chew GT, Bhagat MC, Cussons AJ. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88:4543–4550.
  16. Razvi S, Ingoe LE, McMillan CV, Weaver JU. Health status in patients with sub-clinical hypothyroidism. Eur J Endocrinol. 2005;152(5):713-7.
  17. Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030. PMID: 20103030.
  18. Panicker V, Evans J, Bjøro T, Asvold BO, Dayan CM, Bjerkeset O. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol (Oxf). 2009;71(4):574-80. doi: 10.1111/j.1365-2265.2008.03521.x. PMID: 19751298.
  19. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on ‘adequate’ doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577–585.
  20. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol. 2005;153(6):747-53.
  21. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid. 2007;17(3):249-58.
  22. Ladenson PW. Psychological wellbeing in patients. Clin Endocrinol (Oxf). 2002;57(5):575-6.
  23. Моргунова Т.Б., Мануйлова Ю.А., Мадиярова М.Ш., Лиходей Н.В., Фадеев В.В. Качество жизни пациентов с гипотиреозом. Клиническая и экспериментальная тиреоидология. 2010; 6(2):62 – 67. [Morgunova T, Manuilova Yu, Madyarova M, Lichodei N, Fadeyev V. Quality of life in patients with hypothyroidism. Clinical and experimental thyroidology2010; 6(2):62 – 67]
  24. Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels L, Henley D, Gillett MJ, Gilbert R, Tanner M, Stuckey BG. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab. 2006;91(7):2624-30. Epub 2006 May 2.
  25. Smith RN, Taylor SA, Massey JC. Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. Br Med J. 1970;4(5728):145-8.
  26. Bunevičius R., Kažanavičius G., Žalinkevičius R., Prange A.J. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340(6):424-9.
  27. Bunevicius R1, Jakuboniene N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ Jr. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease. Endocrine. 2002;18(2):129-33.
  28. Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J. Effect of combination therapy with thyroxine (T4) and 3,5,3-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161(6):895-902. doi: 10.1530/EJE-09-0542. PMID: 19666698. Epub 2009 Aug 7.
  29. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM. Combinated therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized controlled clinical trial. J Clin Endocrinol Metab. 2005;90(5):2666-74. Epub 2005 Feb 10.
  30. Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a Combination Regimen of Thyroxine (T4) and 3,5,3'-Triiodothyronine Improve Depressive Symptoms Better Than T4 Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial. J Clin Endocrinol Metab. 2003;88(10):4551-5.
  31. Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab. 1999 Mar;84(3):924-9.
  32. Meier C, Trittibach P, Guglielmetti M, Staub JJ, Müller B. Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey. BMJ. 2003 Feb 8;326(7384):311-2.
  33. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88(6):2438-44.
  34. Chait A, Bierman EL, Albers JJ. Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts. J Clin Endocrinol Metab. 1979;48(5):887-9.
  35. Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA. 2003;290(22):2952-8.
  36. Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, Galán JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142(6):412-24.
  37. Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sänger E, Engel G, Hamm AO, Nauck M, Meng W. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf). 2004; 60:750–757.
  38. Regalbuto C, Maiorana R, Alagona C, Paola RD, Cianci M, Alagona G, Sapienza S, Squatrito S, Pezzino V. Effects of either LT4 monotherapy or LT4/LT3 combined therapy in patients totally thyroidectomized for thyroid cancer. Thyroid. 2007;17:323–331.
  39. Schmidt U, Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J. Peripheral markers of thyroid function: the effect of T4 monotherapy vs T4/T3 combination therapy in hypothyroid subjects in a randomized crossover study. Endocr Connect. 2013;2(1):55-60. doi: 10.1530/EC-12-0064. PMID: 23781319. Print 2013 Mar 1.
  40. Hennemann G, Docter R, Visser TJ, Postema PT, Krenning EP. Thyroxine plus low-dose, slow release triiodothyronine replacement in hypothyroidism: proof of principle. Thyroid 2004;14:271–275.
  41. Alevizaki M, Mantzou E, Cimponeriu AT. Evidence for tissue hypothyroidism in treated hypothyroid patients with “euthyroid” TSH levels. J. Endocrinol. Invest. 2002; 25(Suppl. no.7):83.
  42. Woeber K.A. Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations. J Endocrinol. Invest. 2002; 25:106-110.
  43. Ross D.S. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am. 2001;30(2):245-64, vii.
  44. Salmon D, Rendell M, Williams J, Smith C, Ross DA, Waud JM, Howard JE. Chemical hyperthyroidism: serum triiodothyronine levels in clinically euthyroid individuals treated with levothyroxine. Arch Intern Med. 1982;142(3):571-3.
  45. Escobar-Morreale HF, Obregón MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest. 1995;96(6):2828-38.
  46. Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA. 2008;299(7):769-77. doi: 10.1001/jama.299.7.769. PMID: 18285588.
  47. Celi FS, Zemskova M, Linderman JD, Smith S, Drinkard B, Sachdev V, Skarulis MC, Kozlosky M, Csako G, Costello R, Pucino F. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab. 2011;96(11):3466-74. doi: 10.1210/jc.2011-1329. PMID: 21865366; PMCID: PMC3205882. Epub 2011 Aug 24.
  48. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM. A Common Variation in Deiodinase 1 Gene DIO1 is Associated with the Relative levels of Free Thyroxine and Triiodthyronine. J Clin Endocrinol Metab. 2008;93(8):3075-81. doi: 10.1210/jc.2008-0397. PMID: 18492748; PMCID: PMC2515080. Epub 2008 May 20.
  49. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM. Common variation in the DIO 2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodthyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-9. doi: 10.1210/jc.2008-1301. PMID: 19190113. Epub 2009 Feb 3.
  50. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Fliers E. Polymorphisms in type 2 deiodinase are not associated with wellbeing, neurocognitive functioning, and preference for combined thyroxine/ 3,5,3_-triiodothyronine therapy. J Clin Endocrinol Metab. 2005;90(11):6296-9. Epub 2005 Sep 6.
  51. van der Deure WM, Appelhof BC, Peeters RP, Wiersinga WM, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Visser TJ, Fliers E. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf). 2008 Nov;69(5):804-11. doi: 10.1111/j.1365-2265.2008.03267.x. PMID: 18410547. Epub 2008 Apr 10.

Statistics

Views

Abstract - 1389

PDF (Russian) - 1490

Cited-By


PlumX

Dimensions


Copyright (c) 2015 Morgunova T.B., Madiyarova M.S., Fadeyev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies